Chen Mao

Prof. Chen Mao


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YZYue-Lun Zhang
Yue-Lun Zhang
JYJin-Qiu Yuan
Jin-Qiu Yuan
KWKai-Feng Wang
Kai-Feng Wang
XFXiao-Hong Fu
Xiao-Hong Fu
XHXiao-Ran Han
Xiao-Ran Han
JTJinling Tang
Jinling Tang
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

18 March 2020 in European Heart Journal
Verified
Journal Article
Closed access
TXTian-Yuan Xiong
Tian-Yuan Xiong
SRSimon Redwood
Simon Redwood
BPBernard Prendergast
Bernard Prendergast
CMChen Mao
Chen Mao

1 October 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
ZWZheng-He Wang
Zheng-He Wang
HYHai-Lian Yang
Hai-Lian Yang
YYYun-Qing Yang
Yun-Qing Yang
DLDan Liu
Dan Liu
ZLZhi-Hao Li
Zhi-Hao Li
CMChen Mao
Chen Mao

1 May 2013 in European Urology
Verified
Journal Article
Closed access
JYJinQiu Yuan
JinQiu Yuan
RZRenJie Zhang
RenJie Zhang
ZYZuYao Yang
ZuYao Yang
JLJack Lee
Jack Lee
YLYaLi Liu
YaLi Liu
JTJinLing Tang
JinLing Tang

18 June 2024 in Circulation
Verified
Journal Article
Open access
TLTailuo Liu
Tailuo Liu
YHYing Hao
Ying Hao
ZZZixuan Zhang
Zixuan Zhang
HZHao Zhou
Hao Zhou
SPShiqin Peng
Shiqin Peng
CMChen Mao
Chen Mao
Myocardial infarction is a cardiovascular disease characterized by a high incidence rate and mortality. It leads to various cardiac pathophysiological changes, including ischemia/reperfusion injury, inflammation, fibrosis, and ventricular remodeling, which ultimately result in heart failure and pose a significant threat to global health. Although clinical reperfusion therapies and conventional pharmacological interventions improve emergency survival rates and short-term prognoses, they are still limited in providing long-lasting improvements in cardiac function or reversing pathological progression. Recently, cardiac patches have gained considerable attention as a promising therapy for myocardial infarction. These patches consist of scaffolds or loaded therapeutic agents that provide mechanical reinforcement, synchronous electrical conduction, and localized delivery within the infarct zone to promote cardiac restoration. This review elucidates the pathophysiological progression from myocardial infarction to heart failure, highlighting therapeutic targets and various cardiac patches. The review considers the primary scaffold materials, including synthetic, natural, and conductive materials, and the prevalent fabrication techniques and optimal properties of the patch, as well as advanced delivery strategies. Last, the current limitations and prospects of cardiac patch research are considered, with the goal of shedding light on innovative products poised for clinical application.

1 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
LLLei Luo
Lei Luo
DLDan Liu
Dan Liu
XLXinlong Liao
Xinlong Liao
XWXianbo Wu
Xianbo Wu
QJQinlong Jing
Qinlong Jing
CMChen Mao
Chen Mao
Risk for transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to close contacts of infected persons has not been well estimated. To evaluate the risk for transmission of SARS-CoV-2 to close contacts in different settings. Prospective cohort study. Close contacts of persons infected with SARS-CoV-2 in Guangzhou, China. 3410 close contacts of 391 index cases were traced between 13 January and 6 March 2020. Data on the setting of the exposure, reverse transcriptase polymerase chain reaction testing, and clinical characteristics of index and secondary cases were collected. Measurement: Coronavirus disease 2019 (COVID-19) cases were confirmed by guidelines issued by China. Secondary attack rates in different settings were calculated. Among 3410 close contacts, 127 (3.7% [95% CI, 3.1% to 4.4%]) were secondarily infected. Of these 127 persons, 8 (6.3% [CI, 2.1% to 10.5%]) were asymptomatic. Of the 119 symptomatic cases, 20 (16.8%) were defined as mild, 87 (73.1%) as moderate, and 12 (10.1%) as severe or critical. Compared with the household setting (10.3%), the secondary attack rate was lower for exposures in healthcare settings (1.0%; odds ratio [OR], 0.09 [CI, 0.04 to 0.20]) and on public transportation (0.1%; OR, 0.01 [CI, 0.00 to 0.08]). The secondary attack rate increased with the severity of index cases, from 0.3% (CI, 0.0 to 1.0%) for asymptomatic to 3.3% (CI, 1.8% to 4.8%) for mild, 5.6% (CI, 4.4% to 6.8%) for moderate, and 6.2% (CI, 3.2% to 9.1%) for severe or critical cases. Index cases with expectoration were associated with higher risk for secondary infection (13.6% vs. 3.0% for index cases without expectoration; OR, 4.81 [CI, 3.35 to 6.93]). There was potential recall bias regarding symptom onset among patients with COVID-19, and the symptoms and severity of index cases were not assessed at the time of exposure to contacts. Household contact was the main setting for transmission of SARS-CoV-2, and the risk for transmission of SARS-CoV-2 among close contacts increased with the severity of index cases. Guangdong Province Higher Vocational Colleges and Schools Pearl River Scholar Funded Scheme.